[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Breccia M, Cimino G, Diverio D, Gentilini F, Mandelli F, Lo Coco F: Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica; 2007 Sep;92(9):1273-4
Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia.
  • We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m (2)) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Dose-Response Relationship, Drug. Humans. Male. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768126.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab
  •  go-up   go-down


2. Chandesris MO, Ghez D, Besson C, Suarez F, Delarue R, Rubio MT, Bazarbachi A, Varet B, Hermine O: Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid? BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid?
  • Despite improvements in therapeutic options, human T cell lymphotropic virus type 1 (HTLV-1)-related adult T cell leukaemia/lymphoma (ATLL) has a dismal prognosis.
  • The present report concerns the case of a multirelapsing ATLL that reached a complete remission following the treatment of a secondary acute promyelocytic leukaemia with cytarabine, anthracyclin, all-transretinoic acid and arsenic trioxide.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2007 May;92(5):719-20 [17488707.001]
  • [Cites] Antiviral Res. 2006 Jul;70(3):132-9 [16540180.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2849-55 [11023521.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Hematol J. 2002;3(6):276-82 [12522449.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4576-82 [12560223.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2326-34 [12805334.001]
  • [Cites] J Infect Dis. 2003 Aug 1;188(3):424-7 [12870124.001]
  • [Cites] Haematologica. 2007 Jun;92(6):753-62 [17550847.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:871-7 [15846376.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1010-7 [15843825.001]
  • [Cites] Hematol J. 2004;5(2):130-4 [15048063.001]
  • [Cites] Blood. 1999 Jan 1;93(1):278-83 [9864171.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):347-55 [15621824.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • (PMID = 21829417.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3030139
  •  go-up   go-down


3. Castagnola C, Elena C, Merli M: Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemia. Haematologica; 2008 Feb;93(2):e28
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemia.
  • In this report, we present images from a patient with acute promyelocytic leukemia who experienced several central nervous system relapses.
  • [MeSH-major] Cell Nucleus / pathology. Central Nervous System Neoplasms / pathology. Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Idarubicin. Oncogene Proteins, Fusion / cerebrospinal fluid. Oncogene Proteins, Fusion / genetics. RNA, Neoplasm / cerebrospinal fluid. RNA, Neoplasm / genetics. Recurrence. Remission Induction. Tretinoin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245644.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA, Neoplasm; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; ZRP63D75JW / Idarubicin; AIDA protocol
  •  go-up   go-down


Advertisement
4. Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z: Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci; 2007 Jun 29;362(1482):959-71
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
  • However, we can gain some insight into how this can be done by looking back over the 50-year history of taming acute promyelocytic leukaemia (APL).
  • APL is the M3 type of acute myeloid leukaemia characterized by an accumulation of abnormal promyelocytes in bone marrow, a severe bleeding tendency and the presence of the chromosomal translocation t(15;17) or variants.
  • APL was considered the most fatal type of acute leukaemia five decades ago and the treatment of APL was a nightmare for physicians.
  • The first breakthrough came from the use of anthracyclines which improved the complete remission (CR) rate, though the 5-year overall survival could only be attained in a small proportion of patients.
  • Of note, both ATRA and ATO trigger catabolism of the PML-RARalpha fusion protein which is the key player in APL leukaemogenesis generated from t(15;17), targeting the RARalpha (retinoic acid receptor alpha) or promyelocytic leukaemia (PML) moieties, respectively.
  • Strikingly, a clearance of PML-RARalpha transcript in an earlier and more thorough manner, and a higher quality remission and survival in newly diagnosed APL are achieved when ATRA is combined with ATO, as compared to either monotherapy, making APL a curable disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use. Tretinoin / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Hematol. 2001 Jan;38(1):26-36 [11172537.001]
  • [Cites] J Exp Med. 2001 Feb 19;193(4):531-43 [11181704.001]
  • [Cites] Nat Med. 2001 Jun;7(6):680-6 [11385504.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3919-24 [11389035.001]
  • [Cites] J Exp Med. 2001 Jun 18;193(12):1361-71 [11413191.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] Oncogene. 2001 Oct 29;20(49):7223-33 [11704850.001]
  • [Cites] Oncogene. 2001 Oct 29;20(49):7257-65 [11704854.001]
  • [Cites] Blood. 2002 Feb 1;99(3):759-67 [11806975.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1014-22 [11807007.001]
  • [Cites] Cell. 2002 Jan 25;108(2):165-70 [11832207.001]
  • [Cites] Oncologist. 2002;7 Suppl 1:1-13 [11961204.001]
  • [Cites] Blood. 2002 May 1;99(9):3136-43 [11964275.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8283-8 [12060771.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3893-903 [12124315.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):705-13 [12209159.001]
  • [Cites] J Exp Med. 2002 Nov 18;196(10):1373-80 [12438428.001]
  • [Cites] Curr Drug Metab. 2003 Feb;4(1):1-10 [12570742.001]
  • [Cites] FEBS Lett. 2003 Mar 13;538(1-3):117-24 [12633864.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3188-97 [12515727.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2326-34 [12805334.001]
  • [Cites] Br J Haematol. 2003 Aug;122(4):539-53 [12899709.001]
  • [Cites] Cell. 2003 Oct 31;115(3):305-18 [14636558.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9048-57 [14663483.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):389-401 [15093545.001]
  • [Cites] J Exp Med. 2004 Apr 19;199(8):1163-74 [15096541.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1373-9 [15190260.001]
  • [Cites] Nature. 2004 Sep 9;431(7005):205-11 [15356634.001]
  • [Cites] Proc Natl Acad Sci U S A. 1970 Nov;67(3):1542-9 [5274478.001]
  • [Cites] Proc Natl Acad Sci U S A. 1973 Feb;70(2):343-6 [4510279.001]
  • [Cites] Blood. 1973 Apr;41(4):489-96 [4510926.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Lancet. 1977 Mar 5;1(8010):549-50 [65649.001]
  • [Cites] Cancer. 1978 Jun;41(6):2484-90 [274995.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):259-65 [9806544.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1206-16 [12973844.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:1-13 [14633774.001]
  • [Cites] Nature. 1978 Aug 10;274(5671):535-9 [307692.001]
  • [Cites] Br J Haematol. 1978 Dec;40(4):509-17 [365215.001]
  • [Cites] Br J Haematol. 1980 Jan;44(1):169-70 [6929699.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8428-32 [7915840.001]
  • [Cites] Oncogene. 1996 Jan 18;12(2):323-36 [8570209.001]
  • [Cites] EMBO J. 1996 Jan 2;15(1):110-24 [8598193.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3624-9 [8622986.001]
  • [Cites] Leukemia. 1996 Apr;10(4):735-40 [8618456.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]
  • [Cites] Blood. 1996 Oct 15;88(8):2826-32 [8874178.001]
  • [Cites] Blood. 1997 Jan 15;89(2):376-87 [9002938.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2551-6 [9122233.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83 [9108090.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5302-7 [9144232.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] EMBO J. 1998 Jan 2;17(1):61-70 [9427741.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4300-10 [9596679.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2244-51 [9746761.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1043-52 [10190895.001]
  • [Cites] Blood. 1999 May 15;93(10):3167-215 [10233871.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):772-8 [10328107.001]
  • [Cites] Med Oncol. 1999 Apr;16(1):58-64 [10382944.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1062-70 [10400422.001]
  • [Cites] Hum Mol Genet. 1999 Sep;8(9):1741-9 [10441338.001]
  • [Cites] Acta Med Scand. 1957 Nov 29;159(3):189-94 [13508085.001]
  • [Cites] Schweiz Med Wochenschr. 1959 Jun 6;89:604-8 [13799642.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):143-53 [15710327.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8 [15894607.001]
  • [Cites] PLoS Med. 2005 Jan;2(1):e12 [15696202.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1541-50 [10688806.001]
  • [Cites] Cell Death Differ. 2000 May;7(5):447-60 [10800078.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 May;77(5):2936-40 [6930676.001]
  • [Cites] Med Pediatr Oncol. 1981;9(1):5-15 [6936607.001]
  • [Cites] Blood. 1981 Jun;57(6):1000-4 [6939451.001]
  • [Cites] Br J Haematol. 1982 Feb;50(2):201-14 [6949609.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):18-25 [3855265.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Am J Med. 1986 May;80(5):789-97 [3458366.001]
  • [Cites] Cancer. 1988 Jan 1;61(1):7-13 [3422032.001]
  • [Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]
  • [Cites] Clin Exp Immunol. 1990 Mar;79(3):448-53 [2317949.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1704-9 [2224119.001]
  • [Cites] N Engl J Med. 1991 May 16;324(20):1385-93 [1850498.001]
  • [Cites] Chin Med Sci J. 1991 Jun;6(2):65-70 [1804379.001]
  • [Cites] Blood. 1992 Apr 15;79(8):1916-9 [1562718.001]
  • [Cites] Ann Hematol. 1992 Jun;64(6):270-2 [1637880.001]
  • [Cites] EMBO J. 1993 Mar;12(3):1161-7 [8384553.001]
  • [Cites] J Korean Med Sci. 1991 Dec;6(4):299-307 [1844638.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2260-7 [8387545.001]
  • [Cites] N Engl J Med. 1993 Jul 15;329(3):177-89 [8515790.001]
  • [Cites] Leukemia. 1994 Aug;8(8):1350-3 [8057672.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1371-7 [10942231.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1496-504 [10942397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10173-8 [10954752.001]
  • [Cites] Blood. 2001 Jan 1;97(1):264-9 [11133770.001]
  • (PMID = 17317642.001).
  • [ISSN] 0962-8436
  • [Journal-full-title] Philosophical transactions of the Royal Society of London. Series B, Biological sciences
  • [ISO-abbreviation] Philos. Trans. R. Soc. Lond., B, Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 90
  • [Other-IDs] NLM/ PMC2435563
  •  go-up   go-down


5. Gupta V, Yi QL, Brandwein J, Lipton JH, Messner HA, Schuh AC, Wells RA, Minden MD: Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL). Leuk Res; 2005 Jan;29(1):113-4
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).
  • The role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL) is undefined at present.
  • The 5-year overall and leukaemia-free survival of study patients was 82% (95% C.I.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Remission Induction. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15541484.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 5688UTC01R / Tretinoin
  •  go-up   go-down


6. Harani MS, Adil SN, Kakepoto GN, Khilji Z, Shaikh U, Khurshid M: Significance of cytogenetic abnormalities in acute myeloid leukaemia. J Pak Med Assoc; 2006 Jan;56(1):9-13
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of cytogenetic abnormalities in acute myeloid leukaemia.
  • OBJECTIVE: To evaluate the role of karyotype in acute myeloid leukaemia (AML) as a predictor of response to induction chemotherapy.
  • Diagnosis of AML was based on FAB criteria, immunophenotyping and cytogenetic studies.
  • They were treated according to standard protocols (combination of anthracycline and cytarabine -3+7) and those who had acute promyelocytic leukaemia additionally received all- trans retinoic acid (ATRA).
  • Half of the (51.2%) patients out of remaining 41 achieved complete remission on bone marrow examination after receiving induction chemotherapy.
  • In favourable risk group 3/3 (100%) achieved complete remission (CR) while 15/32 (46.9%) in intermediate risk group and 3/6 (50%) in unfavourable risk group.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454127.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Latagliata R, Carmosino I, Breccia M, Minni A, Testi A, Iorio N, Lo-Coco F, Avvisati G, Petti MC, Mandelli F, Cimino G: Late relapses in acute promyelocytic leukaemia. Acta Haematol; 2007;117(2):106-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late relapses in acute promyelocytic leukaemia.
  • From January 1988 to December 1997, among 53 acute promyelocytic leukaemia patients in 1st complete remission (CR) after 5 years from diagnosis, we observed 5 late relapses (9.4%) after 60, 61, 71, 101 and 155 months from diagnosis; 3 of those late relapses (7.7%) occurred among 39 patients previously treated with all-trans-retinoic acid.
  • In conclusion, a late relapse occurred in a sizeable fraction of acute promyelocytic leukaemia patients: the high rate of ear involvement might be explained considering the ear as a 'disease sanctuary'.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / pathology

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17135723.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin; AIDA protocol
  •  go-up   go-down


8. Gore SD, Smith BD, Gojo I, Grever M, Kaufmann SH, Letendre L, Leonard DG, Marcucci G, Miller CB, Morris L, Piantadosi S, Prior T, Stock W, Karp JE: Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. Am J Hematol; 2005 Jun;79(2):119-27
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.
  • In a pilot study to reduce the duration of treatment and potential long-term toxicities, 39 patients with acute promyelocytic leukemia in remission received a single cycle of intensive consolidation therapy, followed by intermittent ATRA maintenance.
  • Seven patients have relapsed; all other patients are in molecular remission (median follow-up, 2.75 years).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Anthracyclines / administration & dosage. Antineoplastic Agents / administration & dosage. Bone Marrow / metabolism. Humans. Incidence. Infection / chemically induced. Infection / epidemiology. Middle Aged. Myelodysplastic Syndromes / chemically induced. Neoplasm Recurrence, Local / epidemiology. Pilot Projects. Receptors, Retinoic Acid / metabolism. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Stomatitis / chemically induced. Stomatitis / epidemiology. Survival Analysis. Treatment Outcome. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929100.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 5688UTC01R / Tretinoin
  •  go-up   go-down


9. Barbarroja N, Siendones E, Torres LA, Luque MJ, Martinez JM, Dorado G, Velasco F, Torres A, López-Pedrera C: MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia. Br J Haematol; 2008 Jul;142(1):27-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.
  • The hallmark of acute promyelocytic leukaemia (APL) is the reciprocal translocation t(15;17), which leads to the expression of the promyelocytic leukaemia/retinoic acid receptor alpha (PML/RARalpha) fusion protein and a cell differentiation blockade at the promyelocytic stage.
  • PML/RARalpha is directly targeted by all-trans-retinoic acid (ATRA), which degrades the oncoprotein and induces complete remission of malignancies.
  • [MeSH-major] Caspases / metabolism. Cell Transformation, Neoplastic / metabolism. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. Leukemia, Promyelocytic, Acute / metabolism. Oncogene Proteins, Fusion / metabolism. Protein Kinase Inhibitors / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18445086.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / Protein Kinase Inhibitors; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.22.- / Caspases
  •  go-up   go-down


10. Creutzig U, Zimmermann M, Dworzak M, Urban C, Henze G, Kremens B, Lakomek M, Bourquin JP, Stary J, Reinhardt D: Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol; 2010 May;149(3):399-409
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses.
  • Acute promyelocytic leukaemia (APL) treatment often includes high cumulative doses of anthracyclines, which can cause long-term cardiotoxicity.
  • Here, we report the favourable outcome in 81 paediatric APL patients treated according to the consecutive acute myeloid leukaemia-Berlin/Frankfurt/Muenster (AML-BFM) trials -93/-98/-2004 with an anthracycline-cytarabine regimen in combination with all-trans-retinoid acid (ATRA).
  • Seventy-five (93%) patients achieved complete remission.
  • [MeSH-major] Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20230404.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin
  •  go-up   go-down


11. Clavio M, Ghiso A, Ghiggi C, Spriano M, Colombo N, Grasso R, Varaldo R, Miglino M, Pierri I, Olcese F, Aquino S, Biasco S, Balleari E, Carella AM, Sessarego M, Gobbi M: Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa. Oncol Rep; 2009 Apr;21(4):1045-52
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa.
  • We conducted a long-term follow-up retrospective study on 91 consecutive newly diagnosed acute promyelocytic leukaemia (APL) patients.
  • Following consolidation, molecular assessment of response was performed on 67 patients, and 66 were found to have achieved cytogenetic and molecular remission (98%).
  • After a median follow-up of 100 months (12-192), 10 of the 75 patients who achieved complete remission (13%) relapsed.
  • Seventy-eight percent of the patients were expected to be alive at 14 years from diagnosis, i.e., 90 and 48% of patients of intermediate-low risk and high risk at presentation, respectively (p=0.0009).
  • Sixty-nine patients were in molecular remission after first-line and/or salvage therapy (74%).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / administration & dosage

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288007.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


12. Ghaffari SH, Rostami S, Bashash D, Alimoghaddam K, Ghavamzadeh A: Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy. Ann Oncol; 2006 Oct;17(10):1553-9
Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy.
  • BACKGROUND: Recently, patients with acute promyelocytic leukaemia (APL) have experienced significant clinical gains after treatment with arsenic trioxide.
  • PATIENTS AND METHODS: Of 95 newly diagnosed APL patients, 85 patients who achieved complete remission (CR) were sequentially evaluated during a 4-60 month period by conventional RT-PCR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831853.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / Protein Isoforms; 0 / Recombinant Fusion Proteins; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 1.1.1.49 / Glucosephosphate Dehydrogenase; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


13. Jeddi R, Hdiji S, Kacem K, Ben Lakhal R, Aissaoui L, Ben Abid H, Belhadj Ali Z, Meddeb B: [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)]. Tunis Med; 2006 Nov;84(11):717-20
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)].
  • BACKGROUND: Acute promyelocytic leukaemia (APL) account for approximately 10% to 15% of all AML in most reports.
  • Clinical features includes the presence in 80% to 90% of patients of a severe hemorrhagic syndrome, a specific balanced translocation between chromosomes 15 and 17 with a fusion of a large pert of the retinoic acid receptor a gene (RARa) on chromosome 17 to a part of the promyelocytic leukaemia (PML) gene on chromosome 15.
  • AIM: of the study was to assess of the therapeutic management of APL 93 protocol in acute promyelocytic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Anthracyclines / administration & dosage. Child. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics. Female. Humans. Male. Middle Aged. Pilot Projects. Receptors, Retinoic Acid. Remission Induction. Retrospective Studies. Survival Analysis. Translocation, Genetic. Tretinoin / administration & dosage. Tunisia

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294898.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 5688UTC01R / Tretinoin
  •  go-up   go-down


14. Stasi R: Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin Biol Ther; 2008 Apr;8(4):527-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
  • OBJECTIVES: To describe the pharmacology of gemtuzumab ozogamicin and to provide an overview of clinical trials in acute myeloid leukaemia.
  • RESULTS/CONCLUSIONS: Gemtuzumab ozogamicin has shown moderate activity as a single agent in patients with CD33-positive refractory or relapsed acute myeloid leukaemia, with more promising results in acute promyelocytic leukaemia.
  • Because of the different mechanisms of action and non-overlapping toxicities, the integration of this immunoconjugate with standard chemotherapy is a rational approach, and Phase III trials are ongoing both in the induction and in the post-remission settings.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antigens, CD / immunology. Antigens, Differentiation, Myelomonocytic / immunology. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunotoxins / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18352855.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Immunotoxins; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab
  • [Number-of-references] 78
  •  go-up   go-down


15. Saikia TK, Bakshi A, Bhagwat R, Tawde S, Nair R, Nair CN, Parikh PM: Outcome of acute myeloid leukaemia in adults: a retrospective analysis. Natl Med J India; 2005 Jan-Feb;18(1):12-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of acute myeloid leukaemia in adults: a retrospective analysis.
  • BACKGROUND: There are little data from India on the management of acute myeloid leukaemia.
  • With better understanding of the biology of the disease, and routine use of high-dose cytarabine as post-remission therapy with or without haematopoietic blood stem cell transplantation (HSCT), the results have improved in the past two decades.
  • METHODS: A total of 166 newly diagnosed patients with AML (excluding acute promyelocytic leukaemia), 15-60 years of age were treated with daunorubicin (60 mg/m2/day x3 days) or idarubicin (12 mg/m2/day x3 days) with cytarabine (100 mg/m2/day continuous i.v. infusion x7 days) induction chemotherapy.
  • Post-remission therapy included 2 cycles of high-dose cytarabine (15-18 g/m2) followed by monthly cycles of outpatient maintenance chemotherapy x4 cycles, consisting of daunorubicin (45 mg/m2 i.v. x1 day and cytarabine 100 mg/ m2 s.c. twice daily x5 days).
  • Six patients in remission received sibling donor allogeneic HSCT.
  • RESULTS: Morphological complete remission was achieved in 69.9% of the patients.
  • The median duration of remission was 12 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Idarubicin / administration & dosage. India. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15835484.001).
  • [ISSN] 0970-258X
  • [Journal-full-title] The National medical journal of India
  • [ISO-abbreviation] Natl Med J India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


16. Koistinen P, Räty R, Itälä M, Jantunen E, Koivunen E, Nousiainen T, Pelliniemi TT, Remes K, Ruutu T, Savolainen ER, Siitonen T, Silvennoinen R, Volin L, Elonen E, Finnish Leukaemia Group: Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group. Eur J Haematol; 2007 Jun;78(6):477-86
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group.
  • OBJECTIVE: To investigate the long-term outcome of idarubicin- and cytarabine-based intensive chemotherapy in adult acute myeloid leukaemia (AML).
  • PATIENTS AND METHODS: A total of 327 consecutive patients with de novo AML (promyelocytic leukaemia excluded) aged 16-65 yr were recruited into the study between September 1992 and December 2001.
  • After remission achievement with the first (conventional cytarabine) or second (high-dose cytarabine) chemotherapy cycle, three intensive consolidation courses each containing high- or intermediate-dose cytarabine were given.
  • RESULTS: A total of 268 patients (82%) achieved complete remission (CR).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Karyotyping. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17391337.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Makropoulos V, Alexopoulos EC: Case report: Hydroquinone and/or glutaraldehyde induced acute myeloid leukaemia? J Occup Med Toxicol; 2006;1:19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: Hydroquinone and/or glutaraldehyde induced acute myeloid leukaemia?
  • BACKGROUND: Exposures to high doses of irradiation, to chemotherapy, benzene, petroleum products, paints, embalming fluids, ethylene oxide, herbicides, pesticides, and smoking have been associated with an increased risk of acute myelogenous leukemia (AML).
  • Although there in no epidemiological evidence of relation between X-ray developer, fixer and replenisher liquids and AML, these included glutaraldehyde which has weakly associated with lymphocytic leukemia in rats and hydroquinone has been increasingly implicated in producing leukemia, causing DNA and chromosomal damage, inhibits topo-isomerase II, alter hematopoiesis and inhibit apoptosis of neoplastic cells.
  • In July 2001, woman A, 38-years-old, was diagnosed as having acute monocytic leukaemia (FAB M5).
  • In August 2001, woman B, 35-year-old, was diagnosed with acute promyelocytic leukaemia (FAB M3).
  • Since discharge, she is in continuous complete remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 May 1;65(9):3527-30 [15867342.001]
  • [Cites] Toxicol Pathol. 2005;33(4):415-24 [16036858.001]
  • [Cites] Occup Environ Med. 2005 Dec;62(12):861-7 [16299095.001]
  • [Cites] Br J Radiol. 1991 May;64(761):455-60 [2036572.001]
  • [Cites] Toxicol Appl Pharmacol. 1989 Mar 1;97(3):440-53 [2609342.001]
  • [Cites] Australas Radiol. 1986 Aug;30(3):281-6 [3814001.001]
  • [Cites] Ann Occup Hyg. 1993 Jun;37(3):287-95 [8346876.001]
  • [Cites] Br J Ind Med. 1993 Feb;50(2):107-11 [8435342.001]
  • [Cites] Occup Environ Med. 1996 Jul;53(7):450-4 [8704868.001]
  • [Cites] Ann Occup Hyg. 1996 Aug;40(4):423-35 [8806214.001]
  • [Cites] Stem Cells. 1996 Nov;14(6):730-42 [8948030.001]
  • [Cites] Ann Occup Hyg. 1997 Dec;41(6):691-8 [9375527.001]
  • [Cites] Br J Cancer. 1998 Aug;78(3):312-20 [9703276.001]
  • [Cites] Mol Pharmacol. 1999 May;55(5):894-901 [10220568.001]
  • [Cites] J Epidemiol. 1999 Apr;9(2):61-72 [10337078.001]
  • [Cites] Crit Rev Toxicol. 1999 May;29(3):283-330 [10379810.001]
  • [Cites] Exp Hematol. 2000 Feb;28(2):169-76 [10706073.001]
  • [Cites] Occup Med (Lond). 2000 Jan;50(1):39-42 [10795391.001]
  • [Cites] Am J Epidemiol. 2001 Feb 15;153(4):309-18 [11207146.001]
  • [Cites] Leukemia. 2001 Jan;15(1):10-20 [11243376.001]
  • [Cites] Am J Ind Med. 2001 Jul;40(1):3-14 [11439392.001]
  • [Cites] Health Phys. 2002 Apr;82(4):455-66 [11906134.001]
  • [Cites] Am J Ind Med. 2003 Feb;43(2):132-41 [12541267.001]
  • [Cites] Occup Environ Med. 2003 Apr;60(4):254-61 [12660373.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):3080-9 [12784345.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1296-304 [15129224.001]
  • [Cites] Environ Mol Mutagen. 2004;43(4):258-64 [15141365.001]
  • [Cites] Biochim Biophys Acta. 2004 Sep 6;1690(1):11-21 [15337166.001]
  • [Cites] Chem Res Toxicol. 2005 Apr;18(4):761-70 [15833037.001]
  • (PMID = 16872480.001).
  • [ISSN] 1745-6673
  • [Journal-full-title] Journal of occupational medicine and toxicology (London, England)
  • [ISO-abbreviation] J Occup Med Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1544343
  •  go-up   go-down


18. Yang YM, Liu T: [Complete remission of acute promyelocytic leukemia resisting all-trans retinoic acid of one case treated by tanshinone II A]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov;37(6):965-7
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission of acute promyelocytic leukemia resisting all-trans retinoic acid of one case treated by tanshinone II A].
  • The acute promyelocytic leukemia (APL) with DIC was diagnosed.
  • After 14 week treatment, the patient did not get complete remission.
  • Four weeks later, the bone marrow also became normally, and the patient got a complete remission (CR).
  • [MeSH-major] Drug Resistance, Neoplasm. Leukemia, Promyelocytic, Acute / drug therapy. Phenanthrenes / therapeutic use. Remission Induction / methods. Tretinoin / pharmacology

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236602.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Diterpenes, Abietane; 0 / Phenanthrenes; 03UUH3J385 / tanshinone; 5688UTC01R / Tretinoin
  •  go-up   go-down


19. Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M, Lindmark A, Markevärn B, Nilsson B, Sallerfors B, Brune M: Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. Eur J Haematol; 2009 Aug;83(2):99-107
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
  • In 1997-2003, a protocol for treatment of acute myeloid leukaemia (AML) (except promyelocytic leukaemia) was activated in four Swedish health care regions covering 50% of the national population.
  • Induction failures accounted for 55 patients; 16 early deaths eight of whom had white blood cell (WBC) >100 at diagnosis, and 39 refractory disease.
  • Thus, complete remission (CR) rate was 80%.
  • Median survival time from diagnosis in the whole group was 27 months and 4-yr overall survival (OS) rate was 44%.
  • (ii) a risk-adapted therapy aiming at early allogeneic SCT in patients with a high risk of relapse is hampered by induction deaths, refractory disease, and early relapses; and (iii) high WBC count at diagnosis is confirmed as a strong risk factor for early death but not for relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / therapy. Population Surveillance. Stem Cell Transplantation / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385987.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Pession A, Rondelli R, Basso G, Rizzari C, Testi AM, Fagioli F, De Stefano P, Locatelli F, AML Strategy & Study Committee of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP): Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia; 2005 Dec;19(12):2043-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols.
  • Since 1982, four consecutive studies on childhood acute myeloid leukaemia (AML) (namely LAM-82, -87, -87M and -92) have been conducted in Italy by the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) group.
  • Patients with acute promyelocytic leukaemia (20% of diagnoses) were included in LAM-87 and 87M studies.
  • [MeSH-major] Antineoplastic Protocols / standards. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Infant. Infant, Newborn. Male. Remission Induction / methods. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16107897.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


21. Yamauchi T, Arai H, Taga M, Amaya N, Lee JD, Ueda T: [Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid]. Rinsho Ketsueki; 2005 Mar;46(3):206-10
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid].
  • Remission induction therapy was performed for a 46-year-old Japanese man with acute promyelocytic leukemia using ATRA (45 mg/m2), enocitabine (170 mg/m2, 5 days), and mitoxantrone (4 mg/m2, 3 days).
  • The normal sinus rhythm was restored 15 days thereafter, and the patient eventually reached remission.
  • [MeSH-major] Heart Block / chemically induced. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / adverse effects
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Cytarabine / analogs & derivatives. Drug Administration Schedule. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Pacemaker, Artificial. Remission Induction

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447716.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; 9YVR68W306 / enocitabine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


22. Kim SH, Danilenko M, Kim TS: Differential enhancement of leukaemia cell differentiation without elevation of intracellular calcium by plant-derived sesquiterpene lactone compounds. Br J Pharmacol; 2008 Nov;155(6):814-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential enhancement of leukaemia cell differentiation without elevation of intracellular calcium by plant-derived sesquiterpene lactone compounds.
  • BACKGROUND AND PURPOSE: All-trans retinoic acid (ATRA) induces complete remission in a majority of acute promyelocytic leukaemia patients, but resistance of leukaemic cells to ATRA and its toxicity, such as hypercalcaemia, lead to a limitation of treatment.
  • Here, we investigated the effect of plant-derived sesquiterpene lactone compounds and their underlying mechanisms in ATRA-induced differentiation of human leukaemia HL-60 cells.
  • [MeSH-minor] Calcium Signaling / drug effects. HL-60 Cells. Humans. Leukemia / metabolism. Signal Transduction / drug effects. Tretinoin / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] In Vitro Cell Dev Biol Anim. 1999 Oct;35(9):527-32 [10548434.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1546-53 [9305611.001]
  • [Cites] Cell Growth Differ. 2000 Apr;11(4):191-200 [10775036.001]
  • [Cites] Planta Med. 2000 Oct;66(7):591-5 [11105560.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1224-33 [11504768.001]
  • [Cites] Br J Pharmacol. 2002 Mar;135(5):1235-44 [11877332.001]
  • [Cites] Leukemia. 2002 Apr;16(4):683-92 [11960350.001]
  • [Cites] Nutr Cancer. 2001;41(1-2):135-44 [12094616.001]
  • [Cites] Biochem Pharmacol. 2002 Oct 15;64(8):1233-42 [12234604.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1325-32 [12649194.001]
  • [Cites] J Cell Biochem. 2003 Aug 15;89(6):1087-101 [12898508.001]
  • [Cites] J Pharm Sci. 1978 Mar;67(3):347-50 [641720.001]
  • [Cites] J Exp Med. 1979 Apr 1;149(4):969-74 [219131.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 May;77(5):2936-40 [6930676.001]
  • [Cites] Biochem Biophys Res Commun. 1983 Nov 30;117(1):86-92 [6581807.001]
  • [Cites] Biochem Pharmacol. 1997 Oct 15;54(8):909-15 [9354591.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 18;241(2):419-26 [9425286.001]
  • [Cites] Cancer Lett. 1998 Mar 13;125(1-2):157-64 [9566710.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3163-72 [9679985.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):542-6 [9973197.001]
  • [Cites] Planta Med. 1999 Mar;65(2):126-9 [10193202.001]
  • [Cites] Eur J Pharmacol. 2005 Mar 28;511(2-3):89-97 [15792776.001]
  • [Cites] J Cell Physiol. 2005 Sep;204(3):964-74 [15799027.001]
  • [Cites] Leuk Lymphoma. 2005 Dec;46(12):1829-31 [16263588.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Nov;56(2):261-74 [16236522.001]
  • [Cites] J Cell Biochem. 2006 Feb 1;97(2):327-50 [16178010.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13117-25 [16554308.001]
  • [Cites] Ann N Y Acad Sci. 2006 Dec;1091:368-84 [17341629.001]
  • [Cites] Ann N Y Acad Sci. 2006 Dec;1090:203-8 [17384263.001]
  • [Cites] Anticancer Drug Des. 1993 Aug;8(4):299-322 [8240658.001]
  • [Cites] Acta Haematol. 1987;78 Suppl 1:32-40 [2829487.001]
  • [Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]
  • [Cites] Leuk Res. 1989;13(10):869-74 [2586142.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6268-73 [2400989.001]
  • [Cites] Exp Hematol. 1990 Dec;18(11):1147-51 [2226676.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2483-92 [1702327.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4271-8 [1868447.001]
  • [Cites] Blood. 1993 Jul 15;82(2):625-32 [8101106.001]
  • [Cites] Science. 1994 Aug 12;265(5174):956-9 [8052854.001]
  • [Cites] Cancer Lett. 1994 Aug 15;83(1-2):171-5 [8062212.001]
  • [Cites] Eur J Haematol. 1995 Oct;55(4):275-6 [7589349.001]
  • [Cites] J Biol Chem. 1995 Nov 17;270(46):27489-94 [7499206.001]
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):589-96 [8687102.001]
  • [Cites] Bioorg Med Chem. 1997 Apr;5(4):645-53 [9158862.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 20;89(16):1199-206 [9274914.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5617-23 [10553091.001]
  • (PMID = 18724384.001).
  • [ISSN] 1476-5381
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lactones; 0 / Plant Extracts; 0 / Sesquiterpenes; 5688UTC01R / Tretinoin; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2597232
  •  go-up   go-down


23. Fujita H, Nakaya A, Kato J, Tachibana T, Takemura S, Hyo R, Kawano T, Tanaka M, Taguchi J, Maruta A, Fujimaki K, Kanamori H, Ishigatsubo Y: [Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid]. Rinsho Ketsueki; 2005 Oct;46(10):1095-9
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid].
  • Despite the use of all-trans retinoic acid (ATRA) as the first-line treatment for acute promyelocytic leukemia (APL), relapse occurs in about 20% of cases.
  • Most relapsing APL patients can achieve second remission (CR2) following ATRA combined with chemotherapy or arsenic trioxide.
  • Complete molecular remission has been maintained in the remaining 2 patients.
  • Complete molecular remission has been maintained in all 4 patients (mean follow-up, 3 years 9 months).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Promyelocytic, Acute / therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440769.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


24. Xiong L, Wang Y: Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in HL-60 cells induced by arsenite treatment. J Proteome Res; 2010 Feb 5;9(2):1129-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenic is ubiquitously present in the environment; it is a known human carcinogen and paradoxically it is also a successful drug for the clinical remission of acute promyelocytic leukemia (APL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8 [15894607.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2396-410 [15800332.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1297-310 [15961381.001]
  • [Cites] Mol Cell Biochem. 2005 Nov;279(1-2):123-31 [16283521.001]
  • [Cites] Cell Cycle. 2006 Apr;5(7):750-8 [16582625.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):5977-80 [16778164.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 3;99(1):41-52 [17202112.001]
  • [Cites] J Proteome Res. 2007 Jun;6(6):2105-12 [17472359.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Aug 1;222(3):252-7 [17382983.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1003-11 [18281474.001]
  • [Cites] Carcinogenesis. 2008 Sep;29(9):1831-6 [18321869.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Oct;68(1):12-28 [18396408.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):3729-36 [18642942.001]
  • [Cites] Proteomics. 2009 Apr;9(7):1925-38 [19294697.001]
  • [Cites] Anal Chem. 2009 May 15;81(10):4144-52 [19371058.001]
  • [Cites] J Biol Chem. 2009 May 29;284(22):15233-45 [19349280.001]
  • [Cites] J Proteome Res. 2009 Jun;8(6):3006-19 [19364129.001]
  • [Cites] Biochim Biophys Acta. 2009 Sep;1790(9):863-8 [19168116.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):16023-9 [10821856.001]
  • [Cites] Environ Health Perspect. 2000 Jul;108(7):655-61 [10903620.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1643-8 [11172004.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):249-61 [11312654.001]
  • [Cites] Cancer Lett. 2001 Dec 28;174(2):103-13 [11689285.001]
  • [Cites] Oncogene. 2001 Oct 29;20(49):7146-53 [11704843.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):867-76 [12016162.001]
  • [Cites] Mol Cell Proteomics. 2002 May;1(5):376-86 [12118079.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):705-13 [12209159.001]
  • [Cites] Exp Cell Res. 2002 Sep 10;279(1):80-90 [12213216.001]
  • [Cites] Electrophoresis. 2003 Jul;24(14):2386-404 [12874874.001]
  • [Cites] Cell. 2003 Oct 31;115(3):305-18 [14636558.001]
  • [Cites] Cell Death Differ. 2004 Feb;11(2):135-6 [14647234.001]
  • [Cites] Biochem J. 2004 Sep 1;382(Pt 2):641-50 [15175009.001]
  • [Cites] Proteomics. 2004 Oct;4(10):3246-67 [15378690.001]
  • [Cites] J Biol Chem. 1969 May 10;244(9):2278-85 [5783834.001]
  • [Cites] Bacteriol Rev. 1976 Sep;40(3):681-97 [791237.001]
  • [Cites] J Biochem. 1989 May;105(5):751-5 [2666407.001]
  • [Cites] Biochemistry. 1989 May 30;28(11):4523-30 [2669958.001]
  • [Cites] Mutat Res. 1994 Apr;312(2):111-20 [7510822.001]
  • [Cites] Electrophoresis. 1995 Jun;16(6):1034-59 [7498127.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):745-51 [8631008.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]
  • [Cites] Electrophoresis. 1996 May;17(5):830-8 [8783009.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):219-28 [9219560.001]
  • [Cites] Oncogene. 1998 Apr 30;16(17):2177-83 [9619826.001]
  • [Cites] Annu Rev Nutr. 1998;18:331-51 [9706228.001]
  • [Cites] Environ Health Perspect. 1999 Jul;107(7):593-7 [10379007.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(3):1089-99 [15657435.001]
  • [Cites] Mutat Res. 2005 Mar 7;581(1-2):141-52 [15725613.001]
  • [Cites] Proteomics. 2005 Feb;5(3):796-804 [15682461.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):557-64 [15996700.001]
  • (PMID = 20050688.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA116522-03; United States / NCI NIH HHS / CA / R01 CA116522; United States / NCI NIH HHS / CA / R01 CA 116522; United States / NCI NIH HHS / CA / R01 CA116522-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenites; 0 / Heterogeneous-Nuclear Ribonucleoproteins; EC 2.3.1.85 / Fatty Acid Synthases; N5509X556J / arsenite
  • [Other-IDs] NLM/ NIHMS169080; NLM/ PMC2819029
  •  go-up   go-down


25. Braham Jmili N, Omri H, Senana Sendi H, Fekih S, Hizem S, Sriha B, Khelif A, Saad A, Kortas M: Identification of the translocation t(15;17) in acute myeloid leukemia (AML) initially classified as FAB M1: case report and review of the literature. Clin Lab; 2006;52(3-4):125-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the translocation t(15;17) in acute myeloid leukemia (AML) initially classified as FAB M1: case report and review of the literature.
  • The diagnosis of acute myeloid leukaemia (AML) was then evoked initially.
  • One month later, he was discharged from hospital on hematological and cytogenetic remission.
  • From the biological findings the patient was retrospectively diagnosed as having promyelocytic leukemia (hyperbasophilic form).
  • [MeSH-major] Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Leukemia, Myeloid, Acute / genetics. Leukemia, Promyelocytic, Acute / genetics. Neoplasms, Second Primary / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584058.001).
  • [ISSN] 1433-6510
  • [Journal-full-title] Clinical laboratory
  • [ISO-abbreviation] Clin. Lab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.7 / Peroxidase
  • [Number-of-references] 20
  •  go-up   go-down


26. Gu ZM, Wu YL, Zhou MY, Liu CX, Xu HZ, Yan H, Zhao Y, Huang Y, Sun HD, Chen GQ: Pharicin B stabilizes retinoic acid receptor-α and presents synergistic differentiation induction with ATRA in myeloid leukemic cells. Blood; 2010 Dec 9;116(24):5289-97
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All-trans retinoic acid (ATRA), a natural ligand for the retinoic acid receptors (RARs), induces clinical remission in most acute promyelocytic leukemia (APL) patients through the induction of differentiation and/or eradication of leukemia-initiating cells.
  • Here, we identify a novel natural ent-kaurene diterpenoid derived from Isodon pharicus leaves, called pharicin B, that can rapidly stabilize RAR-α protein in various acute myeloid leukemic (AML) cell lines and primary leukemic cells from AML patients, even in the presence of ATRA, which is known to induce the loss of RAR-α protein.
  • Pharicin B also enhances ATRA-dependent the transcriptional activity of RAR-α protein in the promyelocytic leukemia-RARα-positive APL cell line NB4 cells.
  • [MeSH-major] Cell Differentiation / drug effects. Diterpenes, Kaurane / pharmacology. Leukemia, Myeloid, Acute / drug therapy. Receptors, Retinoic Acid / chemistry. Tretinoin / pharmacology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20739655.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diterpenes, Kaurane; 0 / Receptors, Retinoic Acid; 0 / pharicin B; 0 / retinoic acid receptor alpha; 5688UTC01R / Tretinoin
  •  go-up   go-down


27. Chiou TJ, Chu ST, Tzeng WF, Huang YC, Liao CJ: Arsenic trioxide impairs spermatogenesis via reducing gene expression levels in testosterone synthesis pathway. Chem Res Toxicol; 2008 Aug;21(8):1562-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenic trioxide (As2O3) has recently received a great deal of attention because of its capacity to cause complete remission of acute promyelocytic leukemia (APL).

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630931.001).
  • [ISSN] 1520-5010
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Growth Inhibitors; 0 / Oxides; 0 / RNA, Messenger; 3XMK78S47O / Testosterone; 9002-67-9 / Luteinizing Hormone; 9035-51-2 / Cytochrome P-450 Enzyme System; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


28. Idres N, Marill J, Chabot GG: Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells. Biochem Pharmacol; 2005 Jun 1;69(11):1595-601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells.
  • All-trans retinoic acid (ATRA) can induce complete remission in acute promyelocytic leukemia (APL), but resistance to this treatment develops rapidly partly due to increased ATRA metabolism.
  • Among the cytochrome P450s (CYPs) involved in ATRA metabolism, the ATRA-inducible cytochrome P450 26A1 (CYP26A1) is particularly active although the molecular mechanisms involved in its regulation are not well defined in the target leukemia cells.
  • To study CYP26A1 expression and regulation in APL cells, we used the NB4 promyelocytic leukemia cell line.
  • To further define CYP26A1 induction mechanisms in the NB4 leukemia cells, we used RARs and RXR selective agonists.
  • In conclusion, we have shown that CYP26A1 induction is not essential for the granulocytic maturation of NB4 leukemia cells, and that CYP26A1 induction requires the activation of both RARalpha and RXR in these cells.
  • [MeSH-major] Cytochrome P-450 Enzyme System / biosynthesis. Leukemia, Promyelocytic, Acute / enzymology. Receptors, Retinoic Acid / agonists. Retinoid X Receptors / agonists

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896339.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / Retinoid X Receptors; 0 / retinoic acid receptor alpha; 0 / retinoic acid receptor beta; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / retinoic acid 4-hydroxylase
  •  go-up   go-down


29. Glynn RW, Miller N, Kerin MJ: 17q12-21 - the pursuit of targeted therapy in breast cancer. Cancer Treat Rev; 2010 May;36(3):224-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Finally, RARA may be the key to unlocking the problem of resistance to all-trans retinoic acid (ATRA) in breast cancer sufferers; this treatment has previously been demonstrated to induce remission in over 80% of patients with acute promyelocytic leukaemia (APML).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009. Published by Elsevier Ltd.
  • (PMID = 20100636.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / GRB7 protein, human; 0 / Membrane Proteins; 0 / Receptors, Retinoic Acid; 0 / STARD3 protein, human; 0 / retinoic acid receptor alpha; 149058-53-7 / GRB7 Adaptor Protein; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Number-of-references] 58
  •  go-up   go-down


30. Amadori S, Fenaux P, Ludwig H, O'dwyer M, Sanz M: Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin; 2005 Mar;21(3):403-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Arsenic trioxide delivers high rates of complete clinical remission in patients with relapsed/refractory acute promyelocytic leukaemia (APL), and is associated with high rates of molecular remission as indicated by PCR negativity for the PML-RARalpha gene.
  • Investigations of this agent are ongoing in a range of haematological malignancies, and studies in newly diagnosed APL, acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS), multiple myeloma (MM) and chronic myelogenous leukaemia (CML) are reviewed here using published articles and presentations at international congresses to June 2004.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15811209.001).
  • [ISSN] 0300-7995
  • [Journal-full-title] Current medical research and opinion
  • [ISO-abbreviation] Curr Med Res Opin
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 75
  •  go-up   go-down


31. Westers TM, Houtenbos I, van de Loosdrecht AA, Ossenkoppele GJ: Divergent autologous T cell responses to leukaemic dendritic cells during remission in acute promyelocytic leukaemia. Cell Oncol; 2005;27(4):261-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Divergent autologous T cell responses to leukaemic dendritic cells during remission in acute promyelocytic leukaemia.
  • [MeSH-major] Antigen-Presenting Cells / immunology. Antigen-Presenting Cells / pathology. Dendritic Cells / pathology. Leukemia, Promyelocytic, Acute / immunology. Leukemia, Promyelocytic, Acute / pathology. T-Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308476.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC4615955
  •  go-up   go-down


32. Di Veroli A, Ramadan SM, Divona M, Cudillo L, Giannì L, Wieland S, Giannotti F, Mirabile M, Arcese W, Lo-Coco F: Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid Tamibarotene. Br J Haematol; 2010 Oct;151(1):99-101
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid Tamibarotene.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzoates / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tetrahydronaphthalenes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20618325.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoates; 0 / Tetrahydronaphthalenes; 08V52GZ3H9 / tamibarotene
  •  go-up   go-down


33. Martini V, Minotti C, Breccia M, De Angelis G, Buffolino S, Mariella M, Lo-Coco F, Avvisati G, Cimino G: Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid. Ann Hematol; 2007 Apr;86(4):295-7
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Cardiomyopathies / complications. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Drug Therapy, Combination. Echocardiography. Humans. Male. Middle Aged. Oncogene Proteins, Fusion / genetics. Oxides / therapeutic use. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17136541.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / gemtuzumab; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


34. Dalal BI, Bruyere H, Barnett MJ: Significance of persistent Auer rods and cytogenetic abnormality after first cycle of therapy for acute promyelocytic leukaemia. Br J Haematol; 2007 Jun;137(5):385
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of persistent Auer rods and cytogenetic abnormality after first cycle of therapy for acute promyelocytic leukaemia.
  • [MeSH-major] Bone Marrow Examination. Chromosome Aberrations. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Humans. In Situ Hybridization, Fluorescence. Male. Oncogene Proteins, Fusion / genetics. Remission Induction. Translocation, Genetic. Tretinoin / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2008 Sep;142(6):998-1000 [18544082.001]
  • (PMID = 17374141.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


35. Gallipoli P, Drummond MW: Pseudotumour cerebri as a manageable side effect of prolonged all-trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia. Eur J Haematol; 2009 Mar;82(3):242-3
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudotumour cerebri as a manageable side effect of prolonged all-trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Pseudotumor Cerebri / chemically induced. Pseudotumor Cerebri / therapy. Tretinoin / adverse effects. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Female. Humans. Remission Induction. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Haematol. 2009 May;82(5):411. Drummond, M W [added]
  • (PMID = 19018859.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


36. Pham A, Bahadini B, Alsabeh R, Steinberg A: First reported case of aplastic anemia occurring in a patient after acute promyelocytic leukemia in remission. Clin Adv Hematol Oncol; 2009 Oct;7(10):670-4
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First reported case of aplastic anemia occurring in a patient after acute promyelocytic leukemia in remission.
  • [MeSH-major] Anemia, Aplastic / chemically induced. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adult. Humans. Idarubicin / adverse effects. Male. Remission Induction. Tretinoin / adverse effects


37. Sasaki M, Sugimoto K, Isobe Y, Oshimi K: Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide. Eur J Haematol; 2008 Aug;81(2):160
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
  • [MeSH-major] Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use. Tretinoin / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Middle Aged. Remission Induction. Salvage Therapy

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363868.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down






Advertisement